Atlas Venture Fund X Files Intent to Sell $47.8M in Kymera Therapeutics Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).
Summary
Atlas Venture Fund X, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $47.8 million worth of Kymera Therapeutics common stock.
Key Events · Ownership and Investor Activity · KYMR
-
Proposed Stock Sale
Atlas Venture Fund X, LP intends to sell 410,427 shares of Kymera Therapeutics common stock.
-
Significant Value
The proposed sale has an approximate market value of $47,798,328.42.
-
Institutional Seller
The filer, Atlas Venture Fund X, LP, is a significant institutional shareholder.
-
Ongoing Distribution Trend
This filing adds to a recent trend of substantial insider selling, with over $137 million in net sales by insiders in the last 90 days.
Analysis · KYMR · Life Sciences
This Form 144 filing by a major institutional investor signals a significant intent to reduce its stake in Kymera Therapeutics. The proposed sale of nearly $48 million represents a notable portion of the company's market capitalization and could create selling pressure on the stock. This follows a pattern of distribution by insiders over the past 90 days, totaling over $137 million in sales.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $108.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.